Heart failure is not the end of the story.
Heart failure doesn’t mean your heart has stopped working — it means your heart is struggling to keep up with what your body needs. The name itself is misleading. Your heart is not failing you; something is driving it toward dysfunction, and in most cases those drivers can be identified, addressed, and in many patients meaningfully reversed.
Heart failure affects more than six million Americans, and that number continues to rise. It’s one of the leading causes of hospitalization in adults over 65. But those statistics miss the enormous variation in outcomes — depending on how early the condition is caught, how thoroughly the underlying causes are investigated, and how comprehensively the plan addresses the whole person, not just the pumping function of the heart.
Here’s what we tell every patient: the question is not just “How weak is my heart?” The question is “What is making my heart weak, and what can we do about it?” That shift in thinking — from passive management to active investigation — changes everything.
What is heart failure?
Heart failure is a clinical syndrome in which the heart can’t pump blood efficiently enough to meet the body’s demands. This can happen because the muscle has become too weak to contract forcefully (HFrEF — heart failure with reduced ejection fraction), or too stiff to relax and fill properly (HFpEF — heart failure with preserved ejection fraction). In both cases the result is the same: the body doesn’t get enough blood flow, and fluid backs up in the lungs, legs, or abdomen.
Think of your heart as an engine. In HFrEF, the engine has lost power — still running, but unable to generate enough force. In HFpEF, the engine may still be strong but has become rigid, unable to take in fuel efficiently between cycles. What makes heart failure complex is that it’s almost never a standalone problem — it’s the downstream consequence of conditions building for years: coronary disease, hypertension, diabetes, obesity, valvular disease, arrhythmias, and chronic inflammation. Addressing those upstream drivers, rather than just managing downstream symptoms, is at the core of how we approach this.
The types of heart failure
- HFrEF (reduced EF): the left ventricle has weakened and EF falls below 40%. Common causes include prior heart attack, long-standing hypertension, alcohol, viral myocarditis, and genetic cardiomyopathies. It has the most robust evidence base for medication and device therapy — which we use aggressively.
- HFpEF (preserved EF): increasingly the dominant form in older adults, particularly women and those with obesity. EF looks normal, but the muscle is stiff and can’t fill properly. Tightly linked to metabolic syndrome — and where our integrative approach makes some of the most dramatic differences, because the standard medication toolkit is far more limited.
- HFmrEF (mildly reduced EF): an intermediate category (EF 41–49%) where patients may be transitioning in either direction. Close monitoring and early intervention can prevent further decline.
- Right-sided heart failure: fluid backs up into the body rather than the lungs, causing swelling in the legs, abdomen, and liver. Often secondary to left-sided failure, but can stem from pulmonary hypertension, chronic lung disease, or severe sleep apnea.
Heart failure doesn’t appear out of nowhere.
It’s the cumulative result of forces acting on the heart over time. Conventional cardiology focuses on the structural damage already done. We go further — investigating what caused the damage, what’s perpetuating it, and what can be done to slow, halt, or reverse it. This is where the real opportunity lies.
Coronary Artery Disease & Prior Heart Attack
The most common cause of HFrEF. When a heart attack damages muscle, the rest must work harder, causing the heart to enlarge and weaken. But the story doesn’t end with the scar — ongoing coronary disease keeps starving the muscle of blood flow. Comprehensive coronary risk management remains essential even after diagnosis.
Hypertension
Chronic high blood pressure forces the heart to pump against resistance with every beat, causing the muscle to thicken and stiffen (left ventricular hypertrophy) — a primary driver of HFpEF. The key question isn’t just the number on the cuff, but why it’s elevated: insulin resistance? cortisol? sleep apnea? We find the answer.
Metabolic Syndrome, Insulin Resistance & Obesity
One of the most significant untapped opportunities in heart failure. Insulin resistance promotes cardiac fibrosis, impairs fuel use, and drives epicardial fat that stiffens the muscle. Obesity adds enormous hemodynamic burden. When the metabolic environment improves, the heart responds — this isn’t theoretical.
Chronic Inflammation
The hidden fire. Chronic systemic inflammation — from metabolic dysfunction, gut dysbiosis, autoimmune conditions, infections, toxins, or stress — directly damages the muscle, promotes fibrosis, and accelerates remodeling. Elevated hsCRP, IL-6, and TNF-alpha independently predict worse outcomes. We measure it and address it.
Hormonal Imbalances
Thyroid dysfunction — even subclinical — impairs cardiac function. The menopausal estrogen decline contributes to diastolic dysfunction and the rising prevalence of HFpEF in women. Testosterone decline in men affects cardiac muscle and exercise capacity. We evaluate hormonal status as integral to management, not an afterthought.
Nutritional Deficiencies & Mitochondrial Dysfunction
The heart beats 100,000+ times a day and runs on mitochondrial energy. Deficiencies in CoQ10 (depleted by statins), magnesium, iron (remarkably common in HF), B vitamins, omega-3s, and vitamin D directly impair contraction and relaxation. We test for these — precision nutrition guided by data, not guessing.
Additional contributing factors
- Autonomic nervous system dysregulation: chronic stress, anxiety, and poor sleep drive sustained sympathetic overdrive — elevating heart rate and cortisol, worsening insulin resistance, and directly stressing a compromised heart. HRV assessment guides targeted regulation.
- Sleep apnea: both a cause and consequence of heart failure, creating a vicious cycle. Treating it can improve symptoms, reduce hospitalizations, and in some cases improve ejection fraction. We screen every patient.
- Toxic exposures & cardiotoxicity: some chemotherapy agents, chronic alcohol (dilated cardiomyopathy), heavy metals, mold/mycotoxins, and environmental chemicals contribute to the total burden the heart must process.
- Arrhythmias, valvular & structural disease: uncontrolled AFib can cause (often reversible) tachycardia-mediated cardiomyopathy; valve disease and cardiomyopathies require thorough structural evaluation.
Symptoms of heart failure
Symptoms can develop gradually — one reason the condition is often diagnosed later than it should be. Many patients live with subtle signs for months or years before diagnosis. Common symptoms include:
- Shortness of breath, particularly with exertion or when lying flat
- Fatigue and reduced exercise tolerance beyond what seems normal for your age
- Swelling in the feet, ankles, legs, or abdomen
- A persistent cough or wheezing, especially when lying down; waking at night gasping for breath
- Rapid or irregular heartbeat; reduced appetite or nausea from abdominal fluid
- Difficulty concentrating; unexplained weight gain from fluid retention
These symptoms are signals, not just inconveniences — each is a clue that guides our investigation. If you’ve been told they’re “just part of getting older,” seek a deeper evaluation. Note: ejection fraction does not necessarily correlate with symptoms; symptoms reflect functional class — your ability to perform specific activities.
The emotional weight of heart failure
The diagnosis itself is terrifying. The word “failure” carries an emotional weight disproportionate to what the condition actually means for many patients — people hear it and think their heart is giving out, that time is running out. For some it triggers grief; for others, a suffocating anxiety where every chest sensation becomes a source of fear. We take this seriously, because emotional distress is not separate from cardiac health — it’s directly connected. Chronic stress and depression activate the sympathetic nervous system, elevate cortisol, increase inflammation, and worsen cardiac function.
What we’ve found is that when patients understand the why behind their heart failure — when they can see the specific drivers and how each piece of their plan targets them — the helplessness lifts. In its place comes a sense of agency. That transformation, from fear to understanding to empowerment, is one of the most meaningful outcomes we provide.
The best of modern cardiology, plus root-cause depth.
We manage heart failure using the full spectrum of evidence-based therapies while simultaneously investigating and addressing the root causes conventional care often overlooks. The goal isn’t just to slow the decline — it’s to give the heart the best possible environment to recover, stabilize, and function.
We don’t guess. We test.
- Cardiac structure & function — echocardiography (EF, wall motion, chamber size, valves, filling pressures).
- Functional capacity — exercise testing, including CPET with VO2 max when appropriate.
- Metabolic health — fasting insulin, glucose, HbA1c, advanced lipid analysis.
- Inflammatory markers — hsCRP and systemic/vascular inflammation.
- Thyroid & hormonal panels — not just TSH, but free T3/T4, antibodies, sex hormones, cortisol.
- Micronutrients — CoQ10, magnesium, iron/ferritin, B vitamins, vitamin D, omega-3.
- Sleep apnea screening, body composition, and toxic burden.
Guideline therapy + creating conditions to heal.
- Guideline-directed medical therapy — ARNI/ACE/ARB, beta-blockers, MRAs, and SGLT2 inhibitors across the EF spectrum.
- Careful diuretic & fluid management; coordination with EP for devices (ICD, CRT) when indicated.
- Metabolic optimization — especially transformative in HFpEF.
- Inflammation reduction and micronutrient repletion based on testing.
- Hormonal & thyroid optimization; aggressive sleep apnea treatment.
- Autonomic regulation — breathwork, HRV biofeedback, stress management — and toxin-burden reduction.
From decline, to stability, to genuine improvement.
Heart failure requires ongoing, attentive management, and we stay with our patients long-term — monitoring cardiac function with periodic echocardiography, tracking biomarkers (BNP/NT-proBNP, inflammatory and metabolic parameters), and adjusting as the picture evolves. As metabolic health improves, inflammation resolves, nutritional status is optimized, and root causes are addressed, many patients experience meaningful improvement.
Some see their ejection fraction recover. Others find symptoms stabilize and quality of life improves substantially even when EF doesn’t change dramatically. The trajectory shifts from decline to stability — and in many cases, from stability to genuine improvement. That’s the power of addressing the whole picture.
Heart failure, answered.
01 Can heart failure be reversed? +
02 What’s the difference between HFrEF and HFpEF? +
03 Why do I still feel terrible even though I’m on heart failure medications? +
04 How important is diet in heart failure management? +
05 Does exercise help or hurt in heart failure? +
06 How does your approach to heart failure differ from a standard cardiologist? +
Give your heart the best environment to recover.
If you’ve been diagnosed with heart failure, are experiencing symptoms that may indicate it, or feel your current plan isn’t addressing the full picture, we’re here to help. Our evaluation goes beyond standard management to investigate the metabolic, inflammatory, hormonal, and nutritional forces that affect your heart — and we build a precision plan to help it function, stabilize, and recover.
Free, no-obligation discovery call. · Call or text 877-511-5166
Speak with a Human →
EVIDENCE
Sources & Citations
+
Guidelines, Epidemiology & Outcomes
- Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. J Am Coll Cardiol. 2022;79(17):e263–e421.
- Sayed A, Vasan RS, Harrell FE, Butler J. Trends in the Prevalence, Associated Risk Factors, and Health Burden of Heart Failure in the United States, 1988 to 2023. J Am Coll Cardiol. 2025;86(25):2542–2564.
- Heart Failure Society of America. HF STATS 2025: Heart Failure Epidemiology and Outcomes Statistics. J Card Fail. 2025.
- Bozkurt B, Ahmad T, Alexander KM, et al. Heart Failure Epidemiology and Outcomes Statistics: A Report of the HFSA. J Card Fail. 2023;29(10):1412–1451.
- Taylor CJ, Ordóñez-Mena JM, Roalfe AK, et al. Trends in Survival After a Diagnosis of Heart Failure in the UK 2000–2017. BMJ. 2019;364:l223.
- Jones NR, Roalfe AK, Adoki I, Hobbs FDR, Taylor CJ. Survival of Patients With Chronic Heart Failure in the Community: A Systematic Review and Meta-Analysis. Eur J Heart Fail. 2019;21(11):1306–1325.
HFrEF, HFpEF & Recovery
- Murphy SP, Ibrahim NE, Januzzi JL. Heart Failure With Reduced Ejection Fraction: A Review. JAMA. 2020;324(5):488–504.
- Cannata A, McDonagh TA. Heart Failure With Preserved Ejection Fraction. N Engl J Med. 2025;392(2):173–184.
- Redfield MM, Borlaug BA. Heart Failure With Preserved Ejection Fraction: A Review. JAMA. 2023;329(10):827–838.
- Cannata A, Crespo-Leiro MG, Bromage DI, Ruschitzka F, McDonagh TA. Heart Failure With Reduced Ejection Fraction. Lancet. 2025.
- Shah KS, Xu H, Matsouaka RA, et al. Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction: 5-Year Outcomes. J Am Coll Cardiol. 2017;70(20):2476–2486.
- Wilcox JE, Fang JC, Margulies KB, Mann DL. Heart Failure With Recovered Left Ventricular Ejection Fraction: JACC Scientific Expert Panel. J Am Coll Cardiol. 2020;76(6):719–734.
- Metra M, Teerlink JR. Heart Failure. Lancet. 2017;390(10106):1981–1995.
Metabolic, Inflammatory & Sleep Drivers
- Murphy SP, Kakkar R, McCarthy CP, Januzzi JL. Inflammation in Heart Failure: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;75(11):1324–1340.
- Khan SS, Berwanger O, Fiuzat M, et al. Prioritising the Primary Prevention of Heart Failure. Lancet. 2025;406(10508):1138–1153.
- Bozkurt B, Aguilar D, Deswal A, et al. Contributory Risk and Management of Comorbidities in Chronic Heart Failure: A Scientific Statement From the AHA. Circulation. 2016;134(23):e535–e578.
- Powell-Wiley TM, Poirier P, Burke LE, et al. Obesity and Cardiovascular Disease: A Scientific Statement From the AHA. Circulation. 2021;143(21):e984–e1010.
- Yeghiazarians Y, Jneid H, Tietjens JR, et al. Obstructive Sleep Apnea and Cardiovascular Disease: A Scientific Statement From the AHA. Circulation. 2021;144(3):e56–e67.
- Javaheri S, Javaheri S, Somers VK, et al. Interactions of Obstructive Sleep Apnea With the Pathophysiology of Cardiovascular Disease, Part 1: JACC State-of-the-Art Review. J Am Coll Cardiol. 2024;84(13):1208–1223.
Iron, CoQ10 & Nutritional Therapy
- Savarese G, von Haehling S, Butler J, et al. Iron Deficiency and Cardiovascular Disease. Eur Heart J. 2023;44(1):14–27.
- Packer M, Anker SD, Butler J, et al. Identification of Three Mechanistic Pathways for Iron-Deficient Heart Failure. Eur Heart J. 2024;45(26):2281–2293.
- Anand IS, Gupta P. Anemia and Iron Deficiency in Heart Failure: Current Concepts and Emerging Therapies. Circulation. 2018;138(1):80–98.
- Al Saadi T, Assaf Y, Farwati M, et al. Coenzyme Q10 for Heart Failure. Cochrane Database Syst Rev. 2021;(2):CD008684.
- Chow SL, Bozkurt B, Baker WL, et al. Complementary and Alternative Medicines in the Management of Heart Failure: A Scientific Statement From the AHA. Circulation. 2023;147(2):e4–e30.
- Raizner AE, Quiñones MA. Coenzyme Q for Patients With Cardiovascular Disease: JACC Focus Seminar. J Am Coll Cardiol. 2021;77(5):609–619.
